MiNK Therapeutics (INKT) Cash from Operations (2020 - 2026)
MiNK Therapeutics (INKT) posted Cash from Operations of 1732597.0 for Q1 2026, up 16.45% sequentially from 2073726.0 in Q4 2025, and down 29.21% YoY from 2447648.42 in Q1 2025.
MiNK Therapeutics (INKT) Cash from Operations (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 1732597.0 in Q1 2026.
- Quarterly Cash from Operations fell 29.21% year-over-year to 1732597.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6316889.0 (up 24.39% YoY) and the FY2025 annual result came in at 5925168.0, up 37.99% from the prior year.
- Cash from Operations advanced to 1732597.0 in Q1 2026 per INKT's latest filing, from 2073726.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 941348.0 in Q3 2025 and troughed at 5614736.0 in Q3 2022.
- A 5-year average of 3049564.47 and a median of 2994922.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 160.27% in 2022, then surged 68.57% in 2025.
- Over 5 years, Cash from Operations stood at 4430522.0 in 2022, then surged by 31.48% to 3035932.0 in 2023, then jumped by 43.09% to 1727667.0 in 2024, then slipped by 20.03% to 2073726.0 in 2025, then gained by 16.45% to 1732597.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 1732597.0, 2073726.0, and 941348.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.08 Mn |
| Jun 30, 2026 | -2.08 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Dec 31, 2025 | -2.07 Mn |
| Dec 31, 2025 | -2.07 Mn |
| Sep 30, 2025 | -941,348.00 |
| Sep 30, 2025 | -941,348.00 |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Mar 31, 2024 | -2.54 Mn |